arginine deiminase

ar·gi·nine de·im·i·nase

an enzyme catalyzing the hydrolytic deamination of l-arginine to l-citrulline and ammonia. Compare: nitric oxide synthase.
References in periodicals archive ?
7) Genomewide association studies have identified variants in potentially pathogenic genes in non-HLA regions, including PTPN22 (8) [protein tyrosine phosphatase, non-receptor type 22 (lymphoid)], the TRAF1-C5 locus [TRAF1 (TNF receptor-associated factor 1) to C5 (complement component 5)], PADI4 (peptidyl arginine deiminase, type IV), and STAT4 (signal transducer and activator of transcription 4).
Genome sequence data from multidrug-resistant USA300 strain FPR3757 showed that it has a novel mobile genetic element that contains genes for enzymes of the arginine deiminase pathway and an oligopeptide permease system (16).
27, 2014 /PRNewswire/ -- Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, acts as a radiosensitizer of pancreatic cancer both in tissue culture and in mice with human pancreatic cancer.
2, 2013 /PRNewswire/ -- Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug Administration (FDA) to begin Phase 1 clinical trials to test ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of acute myeloid leukemia.
6, 2013 /PRNewswire/ -- Polaris Group announced today that the first patient has been dosed in its Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of Relapsed/Refractory Acute Myeloid Leukemia.
28, 2013 /PRNewswire/ -- Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of malignant pleural mesothelioma were presented at the World Conference on Lung Cancer in Sydney, Australia.
29, 2012 /PRNewswire/ --Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in pediatric patients with emphasis on leukemia, lymphoma and sarcoma cancers.
10, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in combination with docetaxel in advanced solid tumors with emphasis on prostate cancer patients.
SAN DIEGO, May 12, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the Company will highlight clinical development plans for its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during a symposium held on Tuesday, May 24, at 1:30 p.
SAN DIEGO, April 11, 2011 /PRNewswire/ -- Polaris Group (Polaris) announced today that data from preclinical studies of ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, is synergistic with hydroxychloroquine (ChQ) in a human pancreatic cancer cell line and with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human melanoma cell lines.
SAN DIEGO, April 8, 2011 /PRNewswire/ -- Polaris Group (Polaris) announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.